# Ultragenyx Pharmaceutical Inc: Phase 3 study terminated, 129 enrolled (Angelman Syndrome)

**Score:** 95/100

| Field | Value |
|---|---|
| Sponsor | Ultragenyx Pharmaceutical Inc |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS) |
| NCT ID | NCT06617429 |
| Phase | Phase 3 |
| Status | terminated |
| Conditions | Angelman Syndrome |
| Intervention types | drug, procedure |
| Target enrollment | 129 |
| Site countries | United States, Canada, Germany, Japan, Poland, Spain |
| Posted | 2024-09-27 |
| Planned start | 2024-12-03 |
| Event | Terminated |
| Event date | 2026-10-30 |
| Last update posted | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.
- Phase 3: multi-site, larger budget.
- 129 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06617429). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.